📇 Rhumatologue · SURESNES CEDEX · (92) · Salarié

M OLIVIER BRUGIERE

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
136 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 SURESNES CEDEX (92)SalariéRPPS 10001469542

11ans d'exercice (thèse 2015)

📊 Reconnaissance scientifique : 30/100📝 104 articles publiés🇫🇷 Publications académiques françaises (8)

✨ Génération du profil synthétique IA en cours…

Thèses universitaires

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Survival benefit of lung transplant for cystic fibrosis since lung allocation score implementation

American journal of respiratory and critical care medicine · 2013

📚 118 citations🎯 RCR 4.64Top 9% NIH🔓 Open Access

Lire l'abstract Crossref ↓

Abstract Rationale The survival benefit of lung transplantation (LT) in adult patients with cystic fibrosis (CF) is debated. Objectives We sought to assess the survival benefit of LT in adult patients with CF. Methods We used data from the United Network for Organ Sharing Registry to identify adult patients with CF on a wait list for LT in the United States between 2005 and 2009. Survival times while on the wait list and after LT were modeled by use of a Cox model that incorporated transplantation status as a time-dependent covariate. Evolution in lung allocation score (LAS) while on the wait list was used as a surrogate for disease severity. We fitted a model for the joint distribution of survival and longitudinal disease process (LAS over time). Measurements and Main Results A total of 704 adult patients with CF were registered on a wait list during the study period. The cumulative incidence of LT was 39.3% (95% confidence interval, 35.6–42.9%) at 3 months and 64.7% (61.0–68.4%) at 12 months, whereas the incidence of death while on the wait list at the same times was 8.5% (6.4–10.6%) and 12.9% (10.3–15.5%), respectively. Survival after LT was 96.5% (94.7–98.2%) at 3 months; 88.4% (85.1–91.8%) at 12 months; and 67.8% (59.9–76.8%) at 3 years. LT conferred a 69% reduction in the instantaneous risk of death (51–80%). The interaction between LAS and LT was significant: the higher the LAS, the greater the survival benefit of LT (P &lt; 0.001). Conclusions LT confers a survival benefit for adult patients with CF.

Lung transplantation in patients with pretransplantation donor-specific antibodies detected by Luminex assay

Transplantation · 2013

📚 69 citations🎯 RCR 2.62Top 19% NIH

Lung transplantation for scleroderma lung disease: An international, multicenter, observational cohort study

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2018

📚 66 citations🎯 RCR 3.58Top 13% NIH🩺 Clinique

Cookies & analyse de trafic

M OLIVIER BRUGIERE

Pourquoi vous devez consulter ce praticien

Thèses universitaires

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal39

Biomarqueurs / Auto-Ac2

Case report / série2

Essai clinique2

Génétique2

Épidémiologie & registres1

IA en rhumatologie1

Revue générale1

Sclérodermie1

Partager cette fiche